References: pubmed links

Perforomist Prescribing Information. Napa, CA: Dey, L.P.; 2007.
Gross NJ, Nelson HS, Lapidus RJ, et al; Formoterol Study Group. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med. 2008;102:189-197.
Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med. 2008;102(4):479-487.
Thomas L. Petty, MD and Dennis E. Doherty, MD. Save Your Breath, America! Prevent Emphysema Now! Advice for Patients Who May be Developing Emphysema or Chronic Bronchitis. Available at: http://www.nlhep.org/resources/saveYourBreath.htm. Accessed June 15, 2005.
Diagnosing COPD/Symptoms of COPD. American Association for Respiratory Care Web site. Available at: http://www.aarc.org/klein/diagnosing.asp. Accessed April 16, 2007.
American Lung Association. Confronting COPD in America: Executive Summary. Available at: http://www.lungusa.org. Accessed April 16, 2007.
About chronic obstructive pulmonary disease (COPD). National Jewish Medical and Research Center Web site. Available at: http://www.njc.org/diseaseinfo/diseases/copd/about/index.aspx. Accessed April 16, 2007.
Recognizing signs and symptoms of COPD. National Jewish Medical and Research Center Web site. Available at: http://www.njc.org/diseaseinfo/diseases/copd/about/symptoms.aspx. Accessed April 16, 2007
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available at: http://www.goldcopd.com/GuidelineList.asp. Accessed April 5, 2007.
Spirometry testing. National Jewish Medical and Research Center Web site. Available at: http://www.njc.org/disease-info/tests/spirometry.aspx. Accessed April 16, 2007.
American Thoracic Society and European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD. Version 12. New York: American Thoracic Society; 2004 [updated 2005 September 8]. Available at: http://www.thoracic.org/go/copd. Accessed April 16, 2007.
Diseases and Conditions Index: Breathing tests. National Heart Lung and Blood Institute Web site. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/Copd/Copd_Diagnosis.asp. Accessed April 16, 2007.
Breathing better with COPD. National Heart Lung and Blood Institute Web site. Available at: http://www.nhlbi.nih.gov/health/public/lung/copd/breathing-better/index.htm. Accessed April 16, 2007.
Smart BA. When asthma and COPD coexist. American Academy of Allergy Asthma & Immunology Web site. Available at: http://www.aaaai.org/patients/seniorsandasthma/when_asthma_copd_coexist.stm. Accessed April 16, 2007.
COPD: breathing techniques. Canadian Lung Association Web site. Available at: http://www.lung.ca/diseases-maladies/copd-mpoc/breathing-respiration/index_e.php. Accessed April 16, 2007.
Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest. 2005;127:335-371.
DuoNeb Prescribing Information. Napa, CA: Dey, L.P.; 2006.
Important information about diskus 20/50. Advair Web site. Available at: http://www.advair.com/copd/opens_airways.asp. Accessed April 16, 2007.
Pulmonary-Allergy Drugs Advisory Committee on the safety of long-acting beta-agonist bronchodilators. Foradil® Aerolizer® (formoterol fumarate inhalation powder) 12 mcg. FDA Pulmonary-Allergy Drugs Advisory Committee Meeting; July 13, 2005. NDA 20-831 Briefing Document.
Tasaka K. Formoterol (Atock): A new orally active and selective beta2-receptor stimulant. Drugs Today. 1986;22:505-519.
Wellness and Lifestyle Articles and Information Index: Eating well when you have chronic obstructive pulmonary disease. Palo Alto Medical Foundation Web site. Available at: http://www.pamf.org/health/healthinfo/index.cfm?A=C&hwid=ug2647. Accessed April 16, 2007.
Exercise training. National Heart Lung and Blood Institute Web site. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/Copd/Copd_Treatments.asp. Accessed April 16, 2007.
Chronic obstructive pulmonary disease: how COPD can be prevented. Centers for Disease Control and Prevention Web site. Available at: http://www.cdc.gov/nceh/airpollution/copd/copdfaq.htm#prevent. Accessed April 16, 2007.
Living with COPD: Exercise. Canadian Lung Association Web site. Available at: http://www.lung.ca/diseases-maladies/copd-mpoc/living-vivre/exercise-exercice_e.php/. Accessed April 16, 2007.
Exercise with COPD. American Association for Respiratory Care Web site. Available at: http://www.aarc.org/patient_education/tips/exercise.asp. Accessed April 16, 2007.
Aerobic exercise: what 30 minutes a day can do. Mayo Clinic Web site. Available at: http://www.mayoclinic.com/health/aerobic-exercise/EP00002/aerobic%20exercise. Accessed April 16, 2007.
Chapter 1: what can exercise do for me?: endurance exercises. US National Institutes of Health National Institute on Aging Web site. Available at: http://www.nia.nih.gov/HealthInformation/Publications/ExerciseGuide/chapter01.htm. Accessed: April 16, 2007.
Lehnert P. Exercises for chronic obstructive pulmonary disease (COPD). Accessed November 28, 2007
COPD: Flare ups: what to do. Available at: http://www.lung.ca/diseases-maladies/copd-mpoc/_e.php. Accessed April 16, 2007.
Keep your home healthy. North Dakota State University, Fargo North Dakota, Web Site. Available at: http://www.ag.ndsu.edu/pubs/ageng/structu/ae1204w.htm. Accessed April 16, 2007.
Dorland’s Illustrated Medical Dictionary, 30th Edition. WB Saunders. Philadelphia, PA, 2003.
Medicine Net. Medical Dictionary. Available at: http://www.medterms.com/script/main/art.asp?articlekey=24664. Accessed April 16, 2007.
Medpage Today. Combination Therapy Reduces COPD Exacerbations. Available at: http://www.medpagetoday.com/tbprint.cfm?tbid=4854&topicid=154. Accessed April 16, 2007.
American Heart Association. Congestive Heart Failure. Available at: http://www.americanheart.org/presenter.jhtml?identifier=4585. Accessed April 16, 2007.
National Heart, Lung, and Blood Institute. Data Fact Sheet: Chronic Obstructive Pulmonary Disease. NIH Publication No. 03-5229. March 2003. Available at: http://www.nhlbi.nih.gov/. Accessed April 16, 2007.
Yahoo Health. Encyclopedia. Available at: http://www.health.yahoo.com/ency/healthwise/hw165533. Accessed September 26, 2007.
MediLexicon International. Pharma-lexicon. Available at: http://www.pharma-lexicon.com/medicaldictionary.php?t=44582. Accessed April 16, 2007.
MedicineNet. Definition of Forced Expiratory Volume. Available at: http://www.medterms.com/script/main/art.asp?articlekey=20404. Accessed April 16, 2007.
GPnotebook. Forced Vital Capacity. Available at: http://www.gpnotebook.co.uk/simplepage.cfm?ID=718274567. Accessed September 26, 2007.
Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ. 2003;326:621 (22 March). Available at: http://www.bmj.com/cgi/content/full/326/7390/621. Accessed April 16, 2007.
WebMD. Asthma Health Center. Available at: http://www.webmd.com/asthma/Using-a-metered-dose-inhaler-MDI. Accessed April 16, 2007.
COPD Guidelines. American Thoracic Society. Available at: http://www.thoracic.org/sections/COPD. Accessed April 16, 2007.
MedlinePlus. Medical Encyclopedia: Pulmonary Function Tests. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/003853.htm. Accessed September 26, 2007.
The Free Dictionary. Available at: http://www.medical-dictionary.thefreedictionary.com/Methylxanthine. Accessed April 16, 2007.
Medicines.org.uk. Available at: http://medguides.medicines.org.uk/document.aspx?name=paradoxical%20bronchospasm. Accessed October 17, 2007.
Chronic Obstructive Pulmonary Disease (COPD) fact sheet. American Lung Association. Available at: http://www.lungusa.org/site/c.dvLUK9O0E/b.4061173/apps/s/content.asp?ct=3052283. Updated September 16, 2008. Accessed September 15,2008.

Please see full Prescribing Information, including Boxed Warning.

Approved Use

Maintenance Treatment of COPD. PERFOROMIST Inhalation Solution is approved for the long-term, twice-daily (morning and evening) use in the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.

Important Safety Information

WARNING: INCREASED RISK OF ASTHMA-RELATED DEATH

PERFOROMIST Inhalation Solution belongs to a class of medications known as long-acting beta₂-adrenergic agonists or LABAs. Long-acting beta₂-adrenergic agonists may increase the risk of asthma-related death. Data from a large placebo-controlled US study comparing the safety of another long-acting beta₂-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting beta₂-adrenergic agonist), the active ingredient in PERFOROMIST Inhalation Solution. [See WARNINGS AND PRECAUTIONS.]

Important Limitations of Use

Deteriorating COPD

PERFOROMIST Inhalation Solution should not be used in patients with rapidly worsening COPD, which may be a life-threatening condition.

Asthma

PERFOROMIST Inhalation Solution is not indicated to treat asthma.

Warnings and Precautions

PERFOROMIST Inhalation Solution should not used for the relief of sudden symptoms, i.e., as rescue therapy for bronchospasm (wheezing or coughing). Sudden symptoms should be treated with a fast-acting rescue inhaler.

Excessive Use of PERFOROMIST Inhalation Solution and Use With Other Long-Acting Beta-Agonists PERFOROMIST Inhalation Solution should not be used more often, or at higher doses than recommended, or with other inhaled, long-acting beta₂-agonists, at the same time because of the risk of an overdose. Serious heart effects and fatalities have been reported with too high doses of inhaled adrenaline-like drugs.

Paradoxical Bronchospasm

As with other inhaled beta₂-agonists, PERFOROMIST Inhalation Solution can produce paradoxical bronchospasm (unexpected tightening of breathing tubes) that may be life threatening. If paradoxical bronchospasm occurs, PERFOROMIST Inhalation Solution should be immediately stopped and a different therapy started.

Cardiovascular Effects

PERFOROMIST Inhalation Solution, like other beta₂-agonists, can produce serious heart-related effects in some patients as measured by higher pulse rate and higher blood pressure.

PERFOROMIST Inhalation Solution should be used with caution in patients with heart disease, especially coronary insufficiency, cardiac arrhythmias, and high blood pressure; in patients with convulsive disorders or thyrotoxicosis; and in patients who are unusually responsive to adrenaline-like drugs.

Coexisting Conditions

PERFOROMIST Inhalation Solution, like other adrenaline-like drugs, should be used with caution in patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to adrenaline-like drugs. Doses of the related beta₂-agonist albuterol, when administered intravenously, have been reported to worsen preexisting diabetes.

Drug Interactions

MAO Inhibitors, Tricyclic Antidepressants and QTc Prolonging Drugs

PERFOROMIST Inhalation Solution, like other beta₂-agonists, should be used with extreme caution in patients being treated with certain antidepressants (monoamine oxidase inhibitors, tricyclic antidepressants), or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be increased by these agents.

Adverse Events

PERFOROMIST Inhalation Solution was studied in a 12-week, double-blind, placebo- and active-controlled trial (123 subjects treated with PERFOROMIST Inhalation Solution) and a 52-week, active-controlled trial (463 subjects treated with PERFOROMIST Inhalation Solution). The most common adverse events reported in patients taking PERFOROMIST Inhalation Solution, and occurring more frequently than in patients taking placebo, were diarrhea (5%), nausea (5%), nasopharyngitis (3%), dry mouth (3%), dizziness (2%), and insomnia (2%).

This Web site provides useful information about chronic obstructive pulmonary disease (COPD) and the maintenance treatment of COPD with PERFOROMIST (formoterol fumarate) Inhalation Solution. Please consult with your healthcare practitioner, who is your best source for diagnosing COPD and recommending appropriate treatment.

PERFOROMIST is a registered trademark of Dey, L.P. DEY^® is a registered trademark of Dey, L.P. U.S. Patent Nos. 6,814,953 and 6,667,344.